Spectrum Pharmaceuticals (NASDAQ:SPPI) Director Rajesh C. Md Shrotriya sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, April 13th. The shares were sold at an average price of $19.93, for a total value of $597,900.00. Following the completion of the transaction, the director now owns 200,652 shares of the company’s stock, valued at $3,998,994.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
NASDAQ:SPPI opened at $19.22 on Monday. Spectrum Pharmaceuticals has a twelve month low of $5.47 and a twelve month high of $23.50. The company has a market cap of $2,104.62, a price-to-earnings ratio of -17.96 and a beta of 1.98.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Spectrum Pharmaceuticals had a negative return on equity of 30.68% and a negative net margin of 70.66%. The firm had revenue of $28.57 million for the quarter, compared to analyst estimates of $33.18 million. During the same period last year, the company earned ($0.10) EPS. The company’s revenue was down 18.9% compared to the same quarter last year. sell-side analysts expect that Spectrum Pharmaceuticals will post -1.14 earnings per share for the current year.
Several equities analysts recently issued reports on the company. BidaskClub lowered Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. ValuEngine upgraded Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. TheStreet lowered Spectrum Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Friday, March 16th. HC Wainwright boosted their price objective on Spectrum Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research report on Monday, February 5th. Finally, Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Spectrum Pharmaceuticals has an average rating of “Buy” and a consensus price target of $25.20.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.